ICH Q14-inspired novel approach to establish an SFC-based purity method for carbamazepine
© 2024 John Wiley & Sons Ltd..
The proposed ICH Q14 guideline "Analytical procedure development" describes science and risk-based approaches for development and maintenance of analytical procedures suitable for the assessment of the quality of drug substances and drug products. As a case study, the systematic development and validation of a supercritical fluid chromatography (SFC)-based purity method for carbamazepine is presented. Systematic analytical quality by design (AQbD) principles were applied using the software package Fusion QbD to the method development approach. The relationship between chromatographic parameters and the responses of interest were examined to improve the reliability of the method by understanding, reducing, and controlling sources of variability. Method performance qualification in terms of method robustness was finally carried out with the parameters that were classified as critical after method development and a validation study met previously set acceptance criteria. The developed SFC purity method for carbamazepine demonstrated readiness as a viable alternative to the official HPLC method published in the Ph.Eur. with improved peak resolution, improved peak symmetry, and faster analysis times (3 min vs. 80 min for the official method). Its inherent reliability illustrates the superiority of AQbD in method development and application for drug quality assurance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Drug testing and analysis - (2024) vom: 15. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schmidt, Alexander H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Analytical quality by design |
|---|
| Anmerkungen: |
Date Revised 16.01.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1002/dta.3635 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367162873 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367162873 | ||
| 003 | DE-627 | ||
| 005 | 20240116232129.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240116s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/dta.3635 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1261.xml |
| 035 | |a (DE-627)NLM367162873 | ||
| 035 | |a (NLM)38225737 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schmidt, Alexander H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ICH Q14-inspired novel approach to establish an SFC-based purity method for carbamazepine |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 John Wiley & Sons Ltd. | ||
| 520 | |a The proposed ICH Q14 guideline "Analytical procedure development" describes science and risk-based approaches for development and maintenance of analytical procedures suitable for the assessment of the quality of drug substances and drug products. As a case study, the systematic development and validation of a supercritical fluid chromatography (SFC)-based purity method for carbamazepine is presented. Systematic analytical quality by design (AQbD) principles were applied using the software package Fusion QbD to the method development approach. The relationship between chromatographic parameters and the responses of interest were examined to improve the reliability of the method by understanding, reducing, and controlling sources of variability. Method performance qualification in terms of method robustness was finally carried out with the parameters that were classified as critical after method development and a validation study met previously set acceptance criteria. The developed SFC purity method for carbamazepine demonstrated readiness as a viable alternative to the official HPLC method published in the Ph.Eur. with improved peak resolution, improved peak symmetry, and faster analysis times (3 min vs. 80 min for the official method). Its inherent reliability illustrates the superiority of AQbD in method development and application for drug quality assurance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ICH Q14 | |
| 650 | 4 | |a SFC | |
| 650 | 4 | |a analytical quality by design | |
| 650 | 4 | |a carbamazepine | |
| 700 | 1 | |a Stanic, Mijo |e verfasserin |4 aut | |
| 700 | 1 | |a Parr, Maria Kristina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug testing and analysis |d 2009 |g (2024) vom: 15. Jan. |w (DE-627)NLM196999022 |x 1942-7611 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:15 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/dta.3635 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 15 |c 01 | ||